Author:
Tong Yan,Tonui Philip,Orang’o Omenge,Zhang Jianjun,Maina Titus,Muthoka Kapten,Groopman John,Smith Joshua,Madeen Erin,Ermel Aaron,Loehrer Patrick,Brown Darron R.
Abstract
Abstract
Background
Cervical cancer is caused by oncogenic human papillomaviruses (HR-HPV) and is common among Kenyan women. Identification of factors that increase HR-HPV persistence is critically important. Kenyan women exposed to aflatoxin have an increased risk of HR-HPV detection in cervical specimens. This analysis was performed to examine associations between aflatoxin and HR-HPV persistence.
Methods
Kenyan women were enrolled in a prospective study. The analytical cohort for this analysis included 67 HIV-uninfected women (mean age 34 years) who completed at least two of three annual study visits and had an available blood sample. Plasma aflatoxin was detected using ultra-high pressure liquid chromatography (UHPLC)-isotope dilution mass spectrometry. Annual cervical swabs were tested for HPV (Roche Linear Array). Ordinal logistic regression models were fitted to examine associations of aflatoxin and HPV persistence.
Results
Aflatoxin was detected in 59.7% of women and was associated with higher risk of persistent detection of any HPV type (OR = 3.03, 95%CI = 1.08–8.55, P = 0.036), HR-HPV types (OR = 3.63, 95%CI = 1.30-10.13, P = 0.014), and HR-HPV types not included in the 9-valent HPV vaccine (OR = 4.46, 95%CI = 1.13–17.58, P = 0.032).
Conclusions
Aflatoxin detection was associated with increased risk of HR-HPV persistence in Kenyan women. Further studies, including mechanistic studies are needed to determine if aflatoxin synergistically interacts with HR-HPV to increase cervical cancer risk.
Funder
National Cancer Institute, United States
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:398–424.
2. Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2020;9:161–9.
3. Mwenda V, Mburu W, Bor JP, et al. Cervical cancer programme, Kenya, 2011–2020: lessons to guide elimination as a public health problem. Ecancermedicalscience. 2022;16:1442.
4. Organization WH. Cervical cancer Kenya 2021 country profile. Available at: https://www.who.int/publications/m/item/cervical-cancer-ken-country-profile-2021.
5. Brower V. AIDS-related cancers increase in Africa. J Natl Cancer Inst. 2011;103:918–9.